Interleukin-21 engineering enhances CD19-specific CAR-NK cell activity against B-cell lymphoma via enriched metabolic pathways

Interleukin-21 engineering enhances CD19-specific CAR-NK cell activity against B-cell lymphoma via enriched metabolic pathways

Abstract Background NK cells engineered to express interleukin-15 (IL-15) and a CD19-targeted chimeric antigen receptor (CAR) have been used to treat patients with relapsed and/or refractory B cell malignances, demonstrating encouraging outcomes and favorable safety profile. However, the effect of I...

Full description

Saved in:
Bibliographic Details
Main Authors: Bailin He, Hong Chen, Jiaxu Wu, Shiqiu Qiu, Qiusui Mai, Qing Zeng, Cong Wang, Shikai Deng, Zihong Cai, Xiaoli Liu, Li Xuan, Chengyao Li, Hongsheng Zhou, Qifa Liu, Na Xu
Format: Article
Language:English
Published: BMC 2025-04-01
Series:Experimental Hematology & Oncology
Subjects:
Chimeric antigen receptor (CAR)-NK cells
Interleukin-15
Interleukin-21
B-cell malignances
Metabolic fitness
Online Access:https://doi.org/10.1186/s40164-025-00639-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items